title: Brain metastases from gestational trophoblastic neoplasia: review of pertinent literature.
abstract: Brain metastasis from gestational trophoblastic neoplasia (GTN) is rare with about 222 cases documented in the literature and an incidence of about 11% in living GTN patients. Brain metastasis from GTN was part of a disseminated disease in 90% of patients, single metastases in the brain - 80% and located in the cerebrum - 90%. Brain metastasis was the only manifestation of metastatic GTN in 11.3% of patients, appeared synchronously with metastatic GTN in other sites of the body - 30.6% and was diagnosed from 0.3 to 60 months after diagnosis of metastatic GTN in other sites (most often in the lung) - 58.1%. Overall, 83.9% of patients with brain metastases from GTN had also lung metastases from GTN. Brain metastases from GTN showed a greater tendency to be hemorrhagic compared to brain metastases from other primaries. In patients with brain metastases from GTN, the best outcome was achieved with multimodal therapy including craniotomy, whole brain radiotherapy, and EP-EMA or EMA-CO chemotherapy. Nonetheless, brain metastasis from GTN is a grave disease with a median survival time from diagnosis of brain metastasis of about 12 months.
authors.forename: E
authors.initials: E
authors.lastname: Piura
authors.forename: B
authors.initials: B
authors.lastname: Piura
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000556:secondary* / Q000628:therapy; D003399:Craniotomy; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000556:secondary* / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D011247:Pregnancy; D011379:Prognosis; D011878:Radiotherapy; D014594:Uterine Neoplasms / Q000473:pathology*